DES restenosis rates on the rise?
This article was originally published in The Gray Sheet
"As sirolimus-coated stents move into general use, it is likely that the rate of restenosis will be higher than that shown in the SIRIUS trial," Andrew Marks, MD, states in Oct. 2 New England Journal of Medicine editorial. The article accompanies publication of the Johnson & Johnson/Cordis Cypher sirolimus-eluting stent study, in which the device was associated with an 8.9% six-month binary restenosis rate. Marks cites a 121-patient series by Pero Lemos, MD, Erasmus Medical Center, Rotterdam, showing 16% restenosis (1"The Gray Sheet" Sept. 22, 2003, p. 4)...
You may also be interested in...
The revascularization rates associated with Boston Scientific's Taxus paclitaxel-eluting stent in TAXUS IV are "artificially" depressed by the relatively low rate of angiographic follow-up in the trial, according to rival Johnson & Johnson/Cordis
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.